Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"ATPGroup","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery"},{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Intergalactic Therapeutics

    Menu

    Intergalactic Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Intergalactic Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies

              Details:

              IG-002 addresses all forms of ABCA4-related retinopathies, a subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable (12-month) expression of human ABCA4 protein in adult porcine retinas.

              Lead Product(s): IG-002

              Therapeutic Area: Genetic Disease Product Name: IG-002

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Intergalactic Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding

              Details:

              Intergalactic’s non-viral gene therapy deploys two proprietary technologies: 1) C3DNA, covalently closed and circular DNA which relies on a cellfree manufacturing process; and 2) COMET, a clinically advanced, pulsed electric field focal gene therapy delivery system.

              Lead Product(s): Non-viral Based Gene Therapy

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: ATPGroup

              Deal Size: $75.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing October 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY